Merck wins 1st FDA approval for Keytruda
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with asbestos.
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line treatment of advanced or metastatic malignant pleural mesothelioma.
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination therapy for mesothelioma,
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
FiercePharma6d
ESMO: With survival win, Merck's Keytruda redeems itself in early triple-negative breast cancer
In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...
Merck Gets European Panel Backing for Keytruda in Two Gynecologic Cancers
Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
STAT12d
Merck executive plays down impact of new lung cancer drug data on Keytruda
Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...
FiercePharma23h
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Merck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancer
Keytruda shows promise as a first line option in cervical cancer cutting patients' mortality risk by a third in a Phase 3 ...
STAT12d
Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial
In a historic first, a therapy developed by Summit Therapeutics beat Merck blockbuster Keytruda in late-stage lung cancer ...
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
Zacks.com on MSN1d
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?
Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...
Merck & Company Buy Rating Justified by Keytruda’s Performance and Gardasil’s Market Potential
Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).
Keytruda beaten by Summit’s bispecific in NSCLC
The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.